WASHINGTON (PRWEB)
November 17, 2021

The alliance between NHIT and Sanitas USA will focus on incorporating digital health solutions, providing health expertise, impactful patient-centered management practices and the creation of a health safety net. Their strategies and solutions will be provided through an integrated ecosystem of information technology health tools, quality medical assistance, social services, and community engagement to deliver coordinated, equitable, compassionate, and effective services and treatments to help address healthcare disparities in disadvantaged and rural communities. The alliance will initially focus on communities in Florida, Tennessee, Texas, New Jersey, and several U.S. Territories.

For more than a decade, NHIT has been the nation’s leading voice, advocating for the equitable delivery of health IT across all populations and bringing new approaches and insights to transform underserved communities.

“Through countless listening sessions and boots-on-the-ground engagement, we know that people in communities all around us face a complex set of challenges that make it difficult to live healthy lives,” said Luis Belen, NHIT’s Chief Executive Officer. “NHIT’s partnership with Sanitas USA will play a pivotal role in launching digital health initiatives aimed at improving access to quality healthcare and addressing critical social determinants that create barriers to health.”

“Sanitas, and our parent company Keralty, have supported the care of people in underserved communities for more than 40 years,” said Emilio Herrera, Keralty’s Chief Global Officer. “We’re excited to work with NHIT to incorporate culturally-relevant digital health tools to extend the impact and scope of our unique integrated care model that improves access to quality primary and urgent care while reducing the total cost of care. We believe that integrating healthcare with social services and community engagement is a much more effective model than the traditional healthcare system on its own.”

About NHIT

NHIT is a 501(c)3 non-profit organization on a mission to provide equitable access to health technologies and to make sure that these technologies address the needs of underserved communities and communities of color. Since its founding in 2008, NHIT has worked to advance health equity and economic viability on issues such as broadband access, electronic health records, precision medicine, consumer health applications and disaster resiliency. NHIT has collaborated with Amazon Web Services (AWS), and Tyler Technologies to launch the NHIT Data Fusion Center, to tackle and translate social determinants of health (SDoH) data into actionable insights. For more information visit NHIT.org.

About Sanitas, a Keralty company

Sanitas USA is a subsidiary of Keralty, a leading multinational health organization serving more than 5.9 million people with presence in Spain, United States, Mexico, Colombia, Brazil, Venezuela, Peru, and the Philippines. Sanitas also includes educational and socially focused organizations that complement its world of health mission. In the U.S., Sanitas has 58 medical centers serving more than 350,000 patients throughout Florida, Texas, Tennessee, Connecticut, and New Jersey in close partnership with local leading health insurance organizations. Sanitas brings a unique integrated care model that improves access to quality and culturally relevant primary and urgent care while reducing the total cost of care. For more information visit mysanitas.com.

Share article on social media or email:

CHICAGO (PRWEB)
November 17, 2021

Ziegler, a specialty investment bank, is pleased to announce it served as the exclusive financial advisor to CareSignal (St. Louis, MO), the pioneer of Deviceless Remote Patient Monitoring technology, on its acquisition by Lightbeam Health Solutions (Irving, TX), a leading population health management solution.

With this transaction, Lightbeam is now able to integrate scalable, evidence-based remote engagement as well as monitoring capabilities into its core population health offering, which serves more than 42 million patient lives across the United States.

CareSignal brings over 30 condition-specific programs, proven real-world ROI, and a suite of robust AI-based predictive models that complement Lightbeam’s sophisticated population health analytics platform. Combined with the real-time cohort generation capabilities at the core of Lightbeam, CareSignal programs covering chronic conditions, behavioral health, social determinants of health, maternal health, and additional use cases will rapidly generate scalable returns on investment for value-based providers, payers, and self-insured employers.

Together, Lightbeam and CareSignal will deliver best-in-class population-level stratification, actionable real-time insight delivery, and clinical outcomes improvements. Current and future industry partners of both companies will benefit from the validated offerings and deep focus on client success.

Mark Turco, Managing Director in Ziegler’s Healthcare Corporate Finance practice, commented, “We were honored to work with the phenomenal team at CareSignal. The Company has developed a truly unique approach to Remote Patient Monitoring (RPM), and the partnership with Lightbeam provides a tremendous opportunity to further unlock the potential of RPM at population-level scale in value-based care settings. We are thrilled to have represented CareSignal in this transaction.”

Blake Marggraff, CareSignal CEO and Co-Founder stated, “The Ziegler team was a great partner for our organization given their deep domain expertise and ability to articulate the nuanced CareSignal value proposition to the marketplace. We thank them for providing valuable strategic and financial advice throughout the sale process.”

Ziegler’s Corporate Finance team is focused on delivering best-in-class advisory and financing solutions for companies and organizations across the healthcare industry. In our core practice areas of healthcare services, information technology, hospitals and senior living, Ziegler is one of the most active M&A firms offering innovative sell-side, buy-side, recapitalization/restructuring, equity private placement and strategic partnering services.

For more information about Ziegler, please visit us at http://www.ziegler.com.

About Ziegler:

Mark Turco is a Managing Director with Ziegler’s Healthcare Corporate Finance Practice. Mr. Turco specializes in advising healthcare information technology and healthcare services companies on a spectrum of strategic and financing alternatives, including merger and acquisitions, capital raising transactions and partnership development.

Ziegler is a privately held investment bank, capital markets and proprietary investments firm. Specializing in the healthcare, senior living and education sectors, as well as general municipal and structured finance, enables Ziegler to generate a positive impact on the clients and communities it serves. Headquartered in Chicago with regional and branch offices throughout the United States, Ziegler provides its clients with capital raising, strategic advisory services, equity and fixed income sales & trading and research. To learn more, visit http://www.ziegler.com.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

Share article on social media or email:

NEW YORK (PRWEB)
November 17, 2021

Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma. They also identified potential targeted treatments based on the findings, as reported in Science Advances in November.

This is the first study using multi-omics, the integration and analysis of multiple data types, to create a computational model of multiple myeloma, which the scientists named the Multiple Myeloma Patient Similarity Network (MM-PSN). The genes identified in the analysis included some associated with a high risk of relapse.

“Our findings have immediate implications for the development of novel precision medicine tools and clinical trials, as different subgroups of patients may respond to different targeted and immuno- oncology therapies based on their genomic and transcriptomic profiles,” said lead author Alessandro Lagana, PhD, Assistant Professor of Oncological Sciences at The Tisch Cancer Institute at Mount Sinai. “These studies are fundamental to advancing our understanding of myeloma pathology and pave the way for future research into drug repurposing approaches aimed at novel therapies tailored to specific patient subgroups.”

Researchers believe that MM-PSN captures the complexity of multiple myeloma by associating patients with highly similar DNA and RNA profiles to form more granular and homogeneous classes than achieved by previous classifications. Within the MM-PSN model, researchers represented patients as nodes, much as in a social network, that are connected with one another based on how similar their DNA and RNA profiles are.

To create MM-PSN, researchers analyzed five different types of data obtained from DNA and RNA sequencing of 655 newly diagnosed multiple myeloma patients. The analysis of MM-PSN identified three main groups and 12 subgroups enriched for distinct genetic and molecular features, revealing remarkable diversity within previously defined disease subtypes —such as hyperdiploid and MMSET-translocated, which are chromosome abnormalities—and novel insights into the occurrence of primary and secondary genomic alterations within each patient’s cancer.

One of the biggest findings of the MM-PSN is the an abnormality within an area of chromosome 1 being the most important single genetic variant associated with a high risk of relapse; the study suggests that it should now be incorporated into international myeloma staging systems. Researchers also identified new classes of high-risk patients beyond current classifications in multiple myeloma, including one of patients at highest risk of relapse and shortest overall survival, and another that is often associated with more favorable outcomes.

This work was supported by grants from the National Cancer Institute (NCI) (R21-CA209875-01A1; R01-1R01CA244899-01A1), The Tisch Cancer Institute NCI Support Grant (P30 CA196521) and the Multiple Myeloma philanthropic fund. This work was also supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report’s “Honor Roll” of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children’s Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

NAPLES, Fla. (PRWEB)
November 17, 2021

Varian Biopharmaceuticals, Inc. (“VarianBio”), a private, precision oncology company developing novel therapeutics for the treatment of cancer, today announced its President and CEO, Jeffrey Davis, will be presenting at the Inflection Partners Fall Investment Conference entitled “Excellence in Execution.”

The Inflection Partners Fall Conference will take place virtually on November 16-17, 2021, and Mr. Davis is scheduled to present at 2:40 pm ET on Tuesday, November 16, 2021. To register for the Inflection Partners conference, please visit: http://www.inflectionpartnersllc.com/fallconference

This event will feature more than 25 companies, ranging from disruptive seed stage startups to $1bn+ market cap public companies. This year’s conference supports the Travis Manion Foundation (TSF), which strives to unite and strengthen communities by training, developing, and highlighting the role models that lead them. Travis Manion was an experienced and decorated Marine who was killed in action on April 29, 2007, in Iraq. The TSF develops programs, training opportunities, and events designed to empower veterans and families of the fallen while inspiring them to pass their values on to the next generation and the community at large. For more information, please visit travismanion.org.

About Varian Biopharmaceuticals, Inc.

Varian Biopharmaceuticals, Inc. (“VarianBio”) is private precision oncology company developing novel therapeutics for the treatment of cancer. Precision oncology, whereby physicians use DNA testing to look for genetic mutations of the unique tumors, holds the promise of more targeted treatment recommendations with therapies designed to fight specific tumor types. A recently published global Precision Oncology Market analysis by Reports and Data found the global precision oncology market size amounted to US$49.9 billion in 2019 and is expected to grow at a CAGR of 99% over the next eight years to reach US$99.7 billion in 2027. Varian Bio is developing a best-in-class high-potency, specific atypical protein kinase C iota (“aPKCi”) inhibitor for the treatment of various tumor types in multiple formulations. Recent scientific publications have characterized aPKCi as a bonafide oncogene whose activity may play a fundamental role in the regulation of cancer-associated transcription factors including GLI-1 and K-RAS. Varian Bio’s lead drug candidate, VAR-101, being developed in a topical formulation for the treatment of basal cell carcinoma. VAR-102, an oral formulation, is being developed for the treatment of a wide variety of solid tumors where studies have shown potent aPKCi inhibition would be impactful, including non-small cell lung cancer (NSCLC), pancreatic cancer and colorectal cancer. Additionally, Varian Bio is seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. For more information, please visit http://www.varianbio.com.

Forward-Looking Statements – Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and the expectations expressed in forward-looking statements may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates, and assumptions, and are subject to several risks and uncertainties and other influences, over many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company does not undertake to update these forward-looking statements.

Contacts:

Investors and Media

Jeffrey B. Davis

President & CEO

jdavis@varianbio.com

Share article on social media or email:

ST. PAUL, Minn. (PRWEB)
November 17, 2021

MedLearn Media, one of the country’s leading providers of medical coding, documentation, regulatory and compliance education, news and solutions, announced today that Tom Dolan has been appointed the company’s Chief Executive Officer (CEO).

Dolan possesses a 15-year management and leadership track record, including experience in the clinical field, where he specialized in software and complementary products and services. Most recently, he was CEO at RURO, Incorporated, where he drove the company’s transition to cloud services and led ISO 9001 certification of its procedures and other strategic milestones. Other previous relevant roles include management and leadership positions at Brooks Life Science and VUEMED, Inc.

During his tenure at RURO, Dolan served as Vice President of Sales, Chief Operating Officer and CEO; he directed and managed the market-facing and operational portions of the company’s business-to-business initiatives. In these positions, he was responsible for leading the company’s triple-digit revenue growth, including rebranding and developing new product strategies, as well as establishing key partnerships with, and sales to, large pharmaceutical firms, major hospital systems and clinic networks. Dolan’s international successes include several multimillion-dollar contract awards and subsequent on-time solution deployments in Europe and the Middle East, and the establishment of profitable satellite operations in China.

“Tom joins MedLearn as we continue to reinvent our portfolio and seek new ways to create value for our customers,” said Mike Rogge, MedLearn founder and board Chairman. “His exceptional results in markets similar to ours and his vision for value creation are both causing a lot of excitement. MedLearn is celebrating 30 years of operation. What a moment in our history this is!”

“The MedLearn portfolio, which includes coding, compliance and billing best practices guides, news services and solutions, is unrivaled and owns a sterling reputation,” said Dolan. “I have spent my career focused on modernizing offerings like these to be on-demand, “at-your-fingertips” resources, using the most current delivery methods and market channels. This is a remarkable time in MedLearn’s history because the Company has thrived for 30 years and, perhaps more remarkably, because its relevance continues to grow by the decade. I am eager to continue MedLearn’s great legacy and broaden its impact on the field of human medicine.”

About MedLearn Media, Inc.

Based in St. Paul, Minnesota, MedLearn Media, Inc., and its family of brands — MedLearn Publishing, ICD10monitor and RACmonitor — offer trusted expertise to the healthcare industry in the areas of coding, reimbursement and regulatory compliance. MedLearn Media’s industry-leading resources include online news and special reports, blog articles, print and digital books, visual charts, newsletters, webcasts, seminars and on-demand content. For 30 years, healthcare organizations of all types have depended on MedLearn Media to guide them to fiscal integrity, regulatory compliance and peace of mind. For more information, visit http://www.medlearnmedia.com.

Share article on social media or email:

SEATTLE (PRWEB)
November 17, 2021

KitoTech Medical, a medical device company, announces the addition of the microMend® Variety Pack to its growing line of consumer skin closure products. The new product contains three different microMend Skin Closure device sizes, all designed for easy application by consumers. This unique product combination allows them to close most lacerations quickly and easily, whether at home or away.

With its broad range of skin closure devices, the microMend Variety Pack addresses the need to treat wounds of a variety of sizes. Each Variety Pack has a total of five (5) devices including a new device that closes a laceration of 1” in width; two medium-sized devices, ideal for closing most small lacerations; and two narrow devices, perfect for closing smaller lacerations on the fingers, ears and areas around the nose and mouth. All five devices can be used together to close wounds up to 2 ½” in length.

“We are excited to introduce the new microMend Variety Pack to provide consumers with a family of products that can be used to treat nearly all lacerations from the smallest on the fingers to larger wounds on the arms, legs, and other areas of the body. KitoTech is committed to developing wound closure products that meet the growing demand for consumers to treat themselves rather than visiting busy and expensive ERs and Urgent Care Clinics,” said Dr. Ron Berenson, President and CEO of KitoTech Medical.

About microMend®

microMend consists of an array of miniature staples (Microstaples) attached to an adhesive backing that combines the holding strength of stitches with the simplicity of applying a bandage. The Microstaples are tiny and only enter the upper skin layer making them painless. microMend is designed to provide a cost-effective, time saving and easy-to-use option for closing wounds by consumers as well as medical personnel. microMend keeps wounds securely closed allowing them to heal with minimal to no scarring.

About KitoTech Medical

KitoTech Medical, Inc. is a Seattle-based medical device company that spun out of the University of Washington and continues to develop and commercialize products for wound closure and wound care. More information about microMend and KitoTech Medical can be found online at http://www.micromendskinclosure.com.

Share article on social media or email:

WASHINGTON (PRWEB)
November 17, 2021

Concern is on the rise about the ability of people to access the full range of birth control methods, according to a new nationally representative survey of adults age 18-45 released today by Power to Decide. Nearly seven in ten (69%) say they are concerned about future access to birth control (up from 51% in 2020). Democrats (74%), Independents (72%) and Republicans (55%) are all concerned about access to birth control.

In addition, 85% of respondents—including 93% of Independents, 85% of Democrats and 76% of Republicans—believe all people, regardless of who they are, where they live or what their economic status may be deserve access to all methods of birth control. This and other survey findings were released today from Power to Decide in honor of its ninth annual Thanks, Birth Control Day.

“It’s not surprising that a growing number of people are concerned about access to birth control given the ongoing efforts from some elected officials to restrict access to it,” said Raegan McDonald-Mosley, MD, CEO, Power to Decide. “The ability to plan and space out a pregnancy and pursue one’s goals should belong to all people, regardless of who they are or where they live.”

Fully 74% of survey respondents (up from 45% in 2020)—including 71% of Republicans, 74% of Independents and 77% of Democrats—report using some form of contraception to avoid an unplanned pregnancy.

Further, more than half (55% overall, 59% Democrat, 53% Independent and 51% Republican) agree birth control has allowed them to manage health conditions and 67% agree (including 72% of Democrats, 68% of Independents and 60% of Republicans) birth control has helped them work towards educational or professional goals. Finally, 76% (including 79% of Independents, 75% of Democrats and 74% of Republicans) are thankful birth control allowed them to decide if, when and under what circumstances to get pregnant and have a child.

“Today, we proudly celebrate contraception for all it allows us to accomplish for ourselves and our families and for the opportunity to decide if, when and under what circumstances to get pregnant and have a child,” continued Dr. McDonald-Mosley.

Power to Decide’s Thanks, Birth Control survey results are being released in conjunction with the ninth annual Thanks, Birth Control Day, taking place today, Wednesday, Nov. 17. The Centers for Disease Control and Prevention cites birth control as one of the 10 greatest public health achievements of the 20th century because of its profoundly positive impact on women, families, and society.

When more people talk openly about why they use—and are grateful for—birth control, everybody wins. Here are three quick and easy ways to say, “Thanks, Birth Control” with us today:

• 
  Join us today, from 2-3pm ET for our Twitter Storm using #ThxBirthControl. Spread the word on social media sharing why you are thankful for birth control, what birth control gives you the power to decide or how birth control allows people to live their best worry-free sex life. You can browse our toolkit to see pre-written social copy or write your own to help us dominate the conversation online.
• Check out our Thanks, Birth Control swag on our store and rock it year-round, as we celebrate birth control all-day, everyday! Snap a selfie to post on social media with your #ThxBirthControl swag.
• Share your story about the benefits of birth control, why you love birth control and how birth control allows people to live their best worry-free sex life.

Our work would not be possible without generous support from our partners. Power to Decide would like to thank the following for their support and commitment to people’s reproductive health. Thank you for helping us say, Thanks, Birth Control: PRJKT Ruby, Agile Therapeutics, Twentyeight Health, Organon, Mayne Pharma, Bayer Pharmaceuticals, Nurx and the JPB Foundation.

Power to Decide is a private, non-partisan, non-profit organization that works to ensure all people—no matter who they are, where they live or what their economic status might be—have the power to decide if, when and under what circumstances to get pregnant and have a child. Please visit us at http://www.PowerToDecide.org or follow us on Facebook and Twitter.

About the Survey: The study was conducted for Power to Decide via telephone by SSRS, an independent research company. Interviews were conducted on September 21, 2021 – October 7, 2021 among adults ages 18 to 45. A total of 1,005 interviews were conducted, with a margin of error for total respondents of +/-3.95% adjusted for design effect, at the 95% confidence level

Share article on social media or email: